Da-Long Chen

Dr. Da-Long Chen

Division of cardiovascular medicine, China Medical University Hospital, Taichung, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2024 in The American Journal of Emergency Medicine
Verified
Journal Article
Open access
Da-Long ChenDa-Long Chen
Da-Long Chen
CCChia-Min Chung
Chia-Min Chung
GWGuei-Jane Wang
Guei-Jane Wang
Kuan-Cheng ChangKuan-Cheng Chang
Kuan-Cheng Chang
Out-of-hospital cardiac arrest (OHCA) increases lactate levels and reduces albumin levels on admission and tends to lead to a poor neurological prognosis. In our experience, reduced cholesterol levels predict poor neurological prognosis. However, the relationship between cholesterol levels and neurological prognosis in OHCA survivors remains unclear. This retrospective observational study included data from January 2015 to June 2023 on 219 OHCA survivors at our intensive care unit. Patients were categorized into two groups based on cerebral functional classification (CPC) scores: Group A (CPC score of 1 or 2), including patients with a favorable neurological outcome, and Group B (CPC scores of 3 to 5), comprising those with a poor neurological outcome. We analyzed their lactate, albumin levels, and lipid profiles measured at 6 h after resuscitation. A model to predict the neurological prognosis of admission of OHCA survivors was developed. Approximately 40% of the patients had favorable neurological outcomes at the 30-day follow-up. The lactate-to-albumin ratio (LAR) was significantly lower in Group A than in Group B (3.1 vs. 5.0 mmol/dag, p < 0.001). However, the albumin, total cholesterol, and high-density lipoprotein (HDL) cholesterol levels were significantly higher in Group A than in Group B (3.6 vs. 2.9 g/dL, 166.1 vs. 131.4 mg/dL, and 38.8 vs. 29.7 mg/dL, respectively, p < 0.001). Favorable neurological outcome was indicated at the following thresholds: LAR < 3.7 mmol/dag, albumin level > 3.1 g/dL, total cholesterol level > 146.4 mg/dL, and HDL-cholesterol level > 31.9 mg/dL. These findings underscore the high sensitivity and negative predictive value of the biomarkers. Furthermore, the area under the curve values for LAR, albumin, total cholesterol, and HDL-cholesterol levels were 0.70, 0.75, 0.71, and 0.71, respectively. The corresponding odds ratios were 3.37, 7.08, 3.67, and 3.94, respectively. The LAR, albumin, total cholesterol, and HDL-cholesterol levels measured on admission may predict neurological prognosis in OHCA survivors. Thus, routine practice should include the measurement of these biomarkers at 6 h after resuscitation, especially in patients with a lactate level of > 5 mmol/L. ClinicalTrials.gov ID: NCT02633358.

17 May 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Da-Long ChenDa-Long Chen
Da-Long Chen
YLYu-Kai Lin
Yu-Kai Lin
GWGuei-Jane Wang
Guei-Jane Wang
Kuan-Cheng ChangKuan-Cheng Chang
Kuan-Cheng Chang
Out-of-hospital cardiac arrest (OHCA) survivors have more than one-third mortality rate. Numerous inflammatory indicators are available, and it should be feasible to identify a fast and accurate way to aid medical decisions. This retrospective cohort study included 247 patients with OHCA, hospitalized between January 2015 and August 2024. The study was conducted in the intensive care unit of China Medical University Hospital, Taichung, Taiwan. A variety of inflammatory markers, including interleukin-6, neutrophil to high-density lipoprotein cholesterol ratio (NHR), and C-reactive protein, were screened at 24 h after OHCA. The primary endpoint was the 90-day all-cause mortality. Receiver operating characteristic (ROC) curves and Kaplan–Meier survival curves of NHR were analyzed. Possible risk factors for all-cause mortality were estimated by Cox regression modeling. NHR and interleukin-6 were similarly predictive of all-cause mortality in inflammatory response, and both were superior to C-reactive protein at 24 h after OHCA (p < 0.001). The area under the ROC curve of NHR was 0.74 (95% confidence interval [CI]: 0.66–0.81, p < 0.001), sensitivity: 0.68, and specificity: 0.68, and NHR = 16.1. The 90-day all-cause mortality rate for NHR > 16.1 compared to those with NHR ≤ 16.1 was 0.51 and 0.21, respectively, according to Kaplan–Meier curves analysis. The hazard ratio for NHR > 16.1 was 2.54 (95% CI: 1.68–3.82, p < 0.001). An NHR > 16.1 at 24 h after OHCA is a potential inflammatory marker for predicting all-cause mortality.

20 September 2024 in Medicine
Verified
Journal Article
Open access
Da-Long ChenDa-Long Chen
Da-Long Chen
YLYukai Lin
Yukai Lin
PKPoyen Ko
Poyen Ko
JLJenjyh Lin
Jenjyh Lin
CHChih-Yang Huang
Chih-Yang Huang
Kuan-Cheng ChangKuan-Cheng Chang
Kuan-Cheng Chang
Background: Interleukin (IL)-6 is a major inflammatory cytokine that predicts mortality after out-of-hospital cardiac arrest (OHCA). Targeted temperature management (TTM) is associated with improved all-cause mortality in patients with OHCA. However, the effect of TTM on IL-6 production remains unclear. This study investigated whether TTM has additional anti-inflammatory effects after OHCA. Methods: This prospective cohort study included a total of 141 hospitalized patients with OHCA who were treated between January 2015 and June 2023. The study was conducted in the intensive care unit of China Medical University Hospital, Taichung. Postcardiac arrest care included TTM or the control approach (no TTM). The primary outcomes included the 90-day mortality rate and neurologic outcomes after OHCA. Differences between the TTM and control groups were examined using Student t test, chi-square test, and Kaplan–Meier survival curve analysis. Multivariate analysis of variance model was used to examine interaction effects. Results: Plasma IL-6 and IL-6/soluble IL-6 receptor complex levels were measured at 6 and 24 hours after resuscitation. IL-6 and IL-6/soluble IL-6 receptor complex production was lower in the TTM group than in the control group (−50.0% vs +136.7%, P < .001; +26.3% vs +102.40%, P < .001, respectively). In addition, the 90-day mortality rate and poor neurologic outcomes were lower in the TTM group than in the control group (36.8% vs 63.0%, relative risk 0.39, 95% confidence interval 0.24–0.64, P < .001; 65.5% vs 81.5%, relative risk 0.80, 95% confidence interval 0.66–0.98, P = .04). Conclusion: TTM improves both the mortality rate and neurologic outcomes in patients resuscitated from OHCA, possibly by reducing IL-6-induced proinflammatory responses.

13 April 2025 in Biomedicines
Verified
Journal Article
Open access
Da-Long ChenDa-Long Chen
Da-Long Chen
YLYu-Kai Lin
Yu-Kai Lin
GWGuei-Jane Wang
Guei-Jane Wang
Kuan-Cheng ChangKuan-Cheng Chang
Kuan-Cheng Chang
Background: Survivors of out-of-hospital cardiac arrest (OHCA) after external cardiopulmonary resuscitation (ECPR) have a mortality rate as high as 50–70%. The use of vasoactive inotropes worsen the mortality rate at admission. The administration of levosimendan within 72 h of ECPR facilitates extracorporeal membrane oxygenation (ECMO) weaning, so it is important to determine whether levosimendan improves mortality. Methods: This retrospective cohort study included 158 patients with OHCA of cardiac origin who had undergone ECPR and were hospitalized between January 2015 and December 2024. This study was conducted in the intensive care unit of China Medical University Hospital, Taichung, Taiwan. Twenty-three patients received levosimendan within 72 h, whereas the others did not receive levosimendan. Primary endpoints included ECMO weaning failure rate and 90-day all-cause mortality rate. Kaplan–Meier survival curve analysis was also performed. Covariates for all-cause mortality were estimated and adjusted by using Cox regression modeling. Results: The levosimendan group exhibited lower rates of ECMO weaning failure and 90-day all-cause mortality than the control group (13.0% vs. 52.6% and 17.4% vs. 57.0%, respectively; both p < 0.001). The 90-day survival curve analysis revealed that the levosimendan and control groups had survival rates of 82.6% and 43.0%, respectively (log-rank p < 0.001). Administration of levosimendan within 72 h resulted in a odds ratio of 0.36 (95% confidence interval: 0.18−0.79, p = 0.01). Conclusions: Administering levosimendan within 72 h of ECPR could be a protective factor in improving all-cause mortality.

19 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Da-Long ChenDa-Long Chen
Da-Long Chen
YLYu-Kai Lin
Yu-Kai Lin
GWGuei-Jane Wang
Guei-Jane Wang
Kuan-Cheng ChangKuan-Cheng Chang
Kuan-Cheng Chang
Background: Out-of-hospital cardiac arrest (OHCA) survivors after extracorporeal cardiopulmonary resuscitation (ECPR) have a 50-70% mortality rate. However, the use of vasoactive inotropes during the first 24 h worsened the mortality rate. Be-cause of administering inodilators (e.g., levosimendan and milrinone) within 72 h of ECPR could facilitate extracorporeal membrane oxygenation (ECMO) weaning, it is crucial to determine whether the use of inodilators could im-prove mortality rates. Methods: This retrospective cohort study included 158 patients with OHCA of cardiac origin who had undergone ECPR and were hospitalized between January 2015 and December 2024. This study was con-ducted in the intensive care unit of China Medical University Hospital, Tai-chung, Taiwan. Twenty-three patients received levosimendan within 72 h, whereas the others did not receive an inodilator. Primary endpoints included ECMO weaning failure and the 90-day all-cause mortality rate. Kaplan-Meier survival curve analysis was also performed. Possible covariates for all-cause mortality were estimated using Cox regression modeling. Results The levosi-mendan group exhibited lower rates of ECMO weaning failure and 90-day all-cause mortality than the control group (13.0% vs. 52.6% and 17.4% vs. 57.0%, respectively; both p < 0.001). The 90-day survival curve analysis re-vealed that the levosimendan and control groups had survival rates of 0.83 and 0.43, respectively (log-rank p < 0.001). Administration of levosimendan within 72 h resulted in a hazard ratio of 0.30 (95% confidence interval: 0.12−0.75, p = 0.01). Conclusions Administering levosimendan within 72 h of ECPR could be a protective factor in improving all-cause mortality.

15 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
YLYu-Kai Lin
Yu-Kai Lin
Da-Long ChenDa-Long Chen
Da-Long Chen
CHChung-Ho Hsu
Chung-Ho Hsu
HCHui-Wen Chang
Hui-Wen Chang
KLKeng-Yuan Li
Keng-Yuan Li
Kuan-Cheng ChangKuan-Cheng Chang
Kuan-Cheng Chang
Background: Acute pulmonary embolism (PE), particularly massive and high-risk submassive PE, carries mortality rates exceeding 50% and 15%, respectively. Anticoagulation alone does not effectively reduce mortality. Thrombolytic therapy improves outcomes but poses a substantial bleeding risk. Indigo aspiration thrombectomy alleviates right ventricular pressure overload in acute massive or high-risk submassive PE; however, its effect on PE-related mortality is unknown. This study aimed to determine whether Indigo aspiration thrombectomy improved right heart function and reduced PE-related mortality. Methods: This retrospective cohort study included 46 patients diagnosed with acute massive or high-risk submassive PE who underwent Indigo aspiration thrombectomy between January 2020 and August 2025. The study was conducted in the intensive care unit at China Medical University Hospital, Taichung, Taiwan. Efficacy endpoints were right heart parameters; safety endpoints included major bleeding events and 90-day mortality. Kaplan–Meier survival curve analysis was also performed. Results: Indigo aspiration thrombectomy significantly improved right heart parameters. Pulmonary artery (PA) systolic and mean pressures decreased by 23% (from 57.2 to 44.3 mmHg, p = 0.001; from 35.0 to 26.8 mmHg, p < 0.001). PA pulsatility index increased by 50%, and the right ventricular to left ventricular diameter ratio decreased by 30%. For acute massive PE, the major bleeding rate was 31.3% and PE-related mortality was 25.0%. For acute high-risk submassive PE, the major bleeding and PE-related mortality rates were both 3.3%. Conclusions: Indigo aspiration thrombectomy considerably improves right heart failure and may reduce PE-related mortality in patients with acute massive or high-risk submassive PE.